Clinical guidance for the use of trazodone in major depressive disorder and concomitant conditions: pharmacology and clinical practice

Alessandro Cuomo, Andrea Ballerini, Amalia Cecilia Bruni, Paolo Decina, Guido Di Sciascio, Alessio Fiorentini, Francesco Scaglione, Claudio Vampini, Andrea Fagiolini

Research output: Contribution to journalArticle

Abstract

AIM: To provide a review of the clinically relevant evidence pertaining to the use of trazodone in major depressive disorder. METHODS: Medline and Cochrane Library searches were searched using the keywords 'trazodone' AND 'depression', to identify the most relevant literature pertinent to the pharmacological properties of trazodone and its use in clinical practice. Articles that were selected included basic pharmacology papers, clinical trials, clinical practice guidelines, and reviews. Related references were cross checked. European and United States prescribing information was reviewed as well. An effort was made to give weight to the information that was most relevant for daily clinical practice. RESULTS: Trazodone is an antidepressant with a mechanism of action that remains innovative and with a favorable profile for the treatment of depression. The appropriate antidepressant doses are usually 150-300 mg/day and are often higher than the doses that are used when trazodone is prescribed to augment the antidepressant effect of another medication, for instance when trazodone is prescribed to address insomnia in a patient treated with an SSRI. Trazodone is usually well tolerated and has a low risk of anticholinergic side effects, weight gain and sexual side effects. DISCUSSION: Trazodone is an established medication that is efficacious for the treatment of a broad array of depressive symptoms, including symptoms that are less likely to respond to other antidepressants (e.g. SSRI), such as insomnia. As an antidepressant, trazodone has proven as efficacious as the tricyclic and second-generation antidepressants and is tolerated relatively well. Trazodone may be helpful for patients with major depression and comorbid insomnia, anxiety or psychomotor agitation. CONCLUSIONS: Trazodone is efficacious antidepressants with a relatively low risks of side effects such as weight gain, sexual or anticholinergic effects (such as constipation, urinary retention, dry mouth). In addition to being able to control a wide range of depressive symptoms, trazodone may improve sleep and be particularly helpful for patients whose symptoms of depression include insomnia.

Original languageEnglish
Pages (from-to)137-149
Number of pages13
JournalRivista di Psichiatria
Volume54
Issue number4
DOIs
Publication statusPublished - Jul 1 2019

Fingerprint

Trazodone
Clinical Pharmacology
Major Depressive Disorder
Antidepressive Agents
Sleep Initiation and Maintenance Disorders
Depression
Cholinergic Antagonists
Weight Gain
Pharmacology
Psychomotor Agitation
Urinary Retention
Constipation
Practice Guidelines
Libraries
Mouth

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Clinical guidance for the use of trazodone in major depressive disorder and concomitant conditions : pharmacology and clinical practice. / Cuomo, Alessandro; Ballerini, Andrea; Bruni, Amalia Cecilia; Decina, Paolo; Di Sciascio, Guido; Fiorentini, Alessio; Scaglione, Francesco; Vampini, Claudio; Fagiolini, Andrea.

In: Rivista di Psichiatria, Vol. 54, No. 4, 01.07.2019, p. 137-149.

Research output: Contribution to journalArticle

Cuomo, Alessandro ; Ballerini, Andrea ; Bruni, Amalia Cecilia ; Decina, Paolo ; Di Sciascio, Guido ; Fiorentini, Alessio ; Scaglione, Francesco ; Vampini, Claudio ; Fagiolini, Andrea. / Clinical guidance for the use of trazodone in major depressive disorder and concomitant conditions : pharmacology and clinical practice. In: Rivista di Psichiatria. 2019 ; Vol. 54, No. 4. pp. 137-149.
@article{8cf35116a446424d96c567732130d975,
title = "Clinical guidance for the use of trazodone in major depressive disorder and concomitant conditions: pharmacology and clinical practice",
abstract = "AIM: To provide a review of the clinically relevant evidence pertaining to the use of trazodone in major depressive disorder. METHODS: Medline and Cochrane Library searches were searched using the keywords 'trazodone' AND 'depression', to identify the most relevant literature pertinent to the pharmacological properties of trazodone and its use in clinical practice. Articles that were selected included basic pharmacology papers, clinical trials, clinical practice guidelines, and reviews. Related references were cross checked. European and United States prescribing information was reviewed as well. An effort was made to give weight to the information that was most relevant for daily clinical practice. RESULTS: Trazodone is an antidepressant with a mechanism of action that remains innovative and with a favorable profile for the treatment of depression. The appropriate antidepressant doses are usually 150-300 mg/day and are often higher than the doses that are used when trazodone is prescribed to augment the antidepressant effect of another medication, for instance when trazodone is prescribed to address insomnia in a patient treated with an SSRI. Trazodone is usually well tolerated and has a low risk of anticholinergic side effects, weight gain and sexual side effects. DISCUSSION: Trazodone is an established medication that is efficacious for the treatment of a broad array of depressive symptoms, including symptoms that are less likely to respond to other antidepressants (e.g. SSRI), such as insomnia. As an antidepressant, trazodone has proven as efficacious as the tricyclic and second-generation antidepressants and is tolerated relatively well. Trazodone may be helpful for patients with major depression and comorbid insomnia, anxiety or psychomotor agitation. CONCLUSIONS: Trazodone is efficacious antidepressants with a relatively low risks of side effects such as weight gain, sexual or anticholinergic effects (such as constipation, urinary retention, dry mouth). In addition to being able to control a wide range of depressive symptoms, trazodone may improve sleep and be particularly helpful for patients whose symptoms of depression include insomnia.",
author = "Alessandro Cuomo and Andrea Ballerini and Bruni, {Amalia Cecilia} and Paolo Decina and {Di Sciascio}, Guido and Alessio Fiorentini and Francesco Scaglione and Claudio Vampini and Andrea Fagiolini",
year = "2019",
month = "7",
day = "1",
doi = "10.1708/3202.31796",
language = "English",
volume = "54",
pages = "137--149",
journal = "Rivista di Psichiatria",
issn = "0035-6484",
publisher = "Il Pensiero Scientifico Editore s.r.l.",
number = "4",

}

TY - JOUR

T1 - Clinical guidance for the use of trazodone in major depressive disorder and concomitant conditions

T2 - pharmacology and clinical practice

AU - Cuomo, Alessandro

AU - Ballerini, Andrea

AU - Bruni, Amalia Cecilia

AU - Decina, Paolo

AU - Di Sciascio, Guido

AU - Fiorentini, Alessio

AU - Scaglione, Francesco

AU - Vampini, Claudio

AU - Fagiolini, Andrea

PY - 2019/7/1

Y1 - 2019/7/1

N2 - AIM: To provide a review of the clinically relevant evidence pertaining to the use of trazodone in major depressive disorder. METHODS: Medline and Cochrane Library searches were searched using the keywords 'trazodone' AND 'depression', to identify the most relevant literature pertinent to the pharmacological properties of trazodone and its use in clinical practice. Articles that were selected included basic pharmacology papers, clinical trials, clinical practice guidelines, and reviews. Related references were cross checked. European and United States prescribing information was reviewed as well. An effort was made to give weight to the information that was most relevant for daily clinical practice. RESULTS: Trazodone is an antidepressant with a mechanism of action that remains innovative and with a favorable profile for the treatment of depression. The appropriate antidepressant doses are usually 150-300 mg/day and are often higher than the doses that are used when trazodone is prescribed to augment the antidepressant effect of another medication, for instance when trazodone is prescribed to address insomnia in a patient treated with an SSRI. Trazodone is usually well tolerated and has a low risk of anticholinergic side effects, weight gain and sexual side effects. DISCUSSION: Trazodone is an established medication that is efficacious for the treatment of a broad array of depressive symptoms, including symptoms that are less likely to respond to other antidepressants (e.g. SSRI), such as insomnia. As an antidepressant, trazodone has proven as efficacious as the tricyclic and second-generation antidepressants and is tolerated relatively well. Trazodone may be helpful for patients with major depression and comorbid insomnia, anxiety or psychomotor agitation. CONCLUSIONS: Trazodone is efficacious antidepressants with a relatively low risks of side effects such as weight gain, sexual or anticholinergic effects (such as constipation, urinary retention, dry mouth). In addition to being able to control a wide range of depressive symptoms, trazodone may improve sleep and be particularly helpful for patients whose symptoms of depression include insomnia.

AB - AIM: To provide a review of the clinically relevant evidence pertaining to the use of trazodone in major depressive disorder. METHODS: Medline and Cochrane Library searches were searched using the keywords 'trazodone' AND 'depression', to identify the most relevant literature pertinent to the pharmacological properties of trazodone and its use in clinical practice. Articles that were selected included basic pharmacology papers, clinical trials, clinical practice guidelines, and reviews. Related references were cross checked. European and United States prescribing information was reviewed as well. An effort was made to give weight to the information that was most relevant for daily clinical practice. RESULTS: Trazodone is an antidepressant with a mechanism of action that remains innovative and with a favorable profile for the treatment of depression. The appropriate antidepressant doses are usually 150-300 mg/day and are often higher than the doses that are used when trazodone is prescribed to augment the antidepressant effect of another medication, for instance when trazodone is prescribed to address insomnia in a patient treated with an SSRI. Trazodone is usually well tolerated and has a low risk of anticholinergic side effects, weight gain and sexual side effects. DISCUSSION: Trazodone is an established medication that is efficacious for the treatment of a broad array of depressive symptoms, including symptoms that are less likely to respond to other antidepressants (e.g. SSRI), such as insomnia. As an antidepressant, trazodone has proven as efficacious as the tricyclic and second-generation antidepressants and is tolerated relatively well. Trazodone may be helpful for patients with major depression and comorbid insomnia, anxiety or psychomotor agitation. CONCLUSIONS: Trazodone is efficacious antidepressants with a relatively low risks of side effects such as weight gain, sexual or anticholinergic effects (such as constipation, urinary retention, dry mouth). In addition to being able to control a wide range of depressive symptoms, trazodone may improve sleep and be particularly helpful for patients whose symptoms of depression include insomnia.

UR - http://www.scopus.com/inward/record.url?scp=85071178884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071178884&partnerID=8YFLogxK

U2 - 10.1708/3202.31796

DO - 10.1708/3202.31796

M3 - Article

C2 - 31379379

AN - SCOPUS:85071178884

VL - 54

SP - 137

EP - 149

JO - Rivista di Psichiatria

JF - Rivista di Psichiatria

SN - 0035-6484

IS - 4

ER -